Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Novartis’s Kymriah fails in study focused on aggressive B-cell non-Hodgkin lymphoma

Rivals Bristol Myers Squibb and Gilead have succeeded in similar trials.

By Brian Buntz | August 24, 2021

NovartisNovartis (SWX:NOVN) has announced that the genetically modified autologous T cell immunotherapy Kymriah (tisagenlecleucel) failed to meet the primary endpoint in its Phase 3 BELINDA trial. That endpoint involved event-free survival for people with aggressive B-cell non-Hodgkin lymphoma compared to standard of care. To qualify for the study, patients needed to have primary refractory disease or have relapsed within 12 months of receiving first-line treatment. 

Two other companies, Bristol Myers Squibb (NYSE:BMY) and Gilead Sciences (NSDQ:GILD), recently announced successful data in similar studies involving Breyanzi and Yescarta, respectively.

Bristol Myers Squibb received FDA approval for Breyanzi as third-line therapy in February. 

FDA granted accelerated approval to Yescarta for relapsed or refractory follicular lymphoma in March. 

The standard of care in the treatment was salvage chemotherapy. Also known as rescue therapy, salvage chemotherapy involves a therapy administered after a disease fails to respond to standard therapy. Patients who responded to salvage therapy received high-dose chemotherapy and stem cell transplant. 

While Novartis is disappointed in the results, Kymriah “continues to demonstrate durable responses for patients with certain advanced blood cancers in the third-line setting,” said Jeff Legos, executive vice president, global head of oncology & hematology development at Novartis, in a statement. “We remain committed to accelerating development of Kymriah and our next-generation CAR-Ts and anticipate sharing early clinical results for these therapies at an upcoming medical meeting.”

Kymriah is currently FDA indicated for patients aged three to 25 with B-cell precursor acute lymphoblastic leukemia that is refractory or in relapse. It is also indicated for adults with relapsed or refractory large B-cell lymphoma who have received at least two lines of systemic therapy.


Filed Under: clinical trials, Drug Discovery, Oncology
Tagged With: Breyanzi, Bristol-Myers Squibb, Gilead Sciences, Kymriah, Novartis, tisagenlecleucel, Yescarta
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Diversity
Making diversity in clinical research more than a talking point
psychedelic medicine discussed at SXSW
5 headwinds and 5 tailwinds for psychedelic medicine
lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50